Promotion of central nervous system remyelination using monoclonal autoantibodies
OwnerMoses Rodriguez, David J. Miller +1inventors
InventorsMOSES RODRIGUEZ, DAVID J. MILLER, KUNIHIKO ASAKURA
Life of this patent
Estimating the term…
Abstract
Methods are described for treating demyelinating diseases in mammals, such as multiple sclerosis in humans, and viral diseases of the central nervous system of humans and domestic animals, such as post-infectious encephalomyelitis, or prophylactly inhibiting the initiation or progression of demyelination in these disease states, using the monoclonal autoantibodies SCH 94.03, SCH 79.08, O1, O4, A2B5, HNK-1, active fragments thereof and natural or synthetic autoantibodies having the characteristics of mAb SCH 94.03, SCH 79.08, O1, O4, A2B5 and HNK-1.
Claims20
A method of stimulating remyelination of central nervous system axons in a mammal in need of such therapy which comprises administering to said mammal an effective amount of a monoclonal autoantibody of the IgM subtype, or mixtures and/or active fragments thereof, characterized by their polyreactivity, and encoded by unmutated germline genes, and natural or synthetic autoantibodies having the characteristics thereof.
A method of stimulating the proliferation of glial cells in central nervous system axons in a mammal in need of such therapy which comprises administering to said mammal an effective amount of a monoclonal autoantibody of the IgM subtype, or mixtures and/or active fragments thereof, characterized by their polyreactivity, and encoded by unmutated germline genes, and natural or synthetic autoantibodies having the characteristics thereof.
A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of a monoclonal autoantibody of the IgM subtype, or mixtures and/or active fragments thereof, characterized by their polyreactivity, and encoded by unmutated germline genes, and natural or synthetic autoantibodies having the characteristics thereof.
A in vitro method of stimulating the proliferation of glial cells from mixed cell culture comprising:
- a) culturing a mixed cell culture containing glial cells under condition sufficient for cell proliferation;
- b) introducing into the mixed culture an effective amount of a monoclonal autoantibody of the IgM subtype, or mixtures and/or active fragments thereof, characterized by their polyreactivity, and encoded by unmutated germline genes, and natural or synthetic autoantibodies having the characteristics thereof, thereby producing a monoclonal antibody-treated mixed culture;
- c) maintaining the culture of step b) under conditions sufficient for proliferation of monoclonal antibody-treated cells, thereby resulting in the proliferation of glial cells in the mixed culture;
- and
- d) harvesting the glial cells from the mixed culture.
A method of stimulating remyelination of central nervous system axons in a mammal in need of such therapy comprising:
- a) culturing glial cells under conditions sufficient for cell proliferation thereby producing a glial cell culture;
- b) introducing into the glial cell culture an effective amount of a monoclonal autoantibody of the IgM subtype, or mixtures and/or active fragments thereof, characterized by their polyreactivity, and encoded by unmutated germline genes, and natural or synthetic autoantibodies having the characteristics thereof, thereby producing a monoclonal antibody-treated glial cell culture;
- c) maintaining the culture of step b) under conditions sufficient for proliferation of monoclonal antibody-treated cells;
- d) harvesting the monoclonal antibody-treated cells from the culture, thereby obtaining glial cells;
- and
- e) introducing the glial cells obtained in step d) into the central nervous system of the mammal, thereby stimulating remyelination of central nervous system axons.
A pharmaceutical composition comprising, as the active agent, an active fragment of a monoclonal autoantibody of the IgM subtype, or mixtures and/or active fragments thereof, characterized by their polyreactivity, and encoded by unmutated germline genes, and natural or synthetic autoantibodies having the characteristics thereof.
Dependencies are inferred from the claim text.